ImpediMed Raises $2.1 Million in Oversubscribed Share Purchase Plan
ImpediMed has successfully closed an oversubscribed Share Purchase Plan, raising $2.1 million following a $13.2 million institutional placement. The strong shareholder response underscores confidence ahead of a key shareholder vote.
- SPP oversubscribed with $3.5 million applications
- Total capital raised from SPP and placement reaches $15.3 million
- SPP shares priced at $0.007 with attaching and follow-on options
- Shareholder approval sought at 11 June Extraordinary General Meeting
- Issuance of shares and options expected mid-June
Oversubscribed Share Purchase Plan Boosts Capital
ImpediMed Limited (ASX:IPD) has wrapped up its Share Purchase Plan (SPP), raising $2.1 million after the plan was oversubscribed. This follows a $13.2 million institutional placement announced earlier, bringing total fresh equity raised to $15.3 million. The SPP attracted applications totalling $3.5 million, well beyond the initial $2 million target, prompting the board to accept an additional $0.1 million in oversubscriptions with a pro rata scale-back.
Discounted Share Price and Options Sweeten the Deal
Shares under the SPP were priced at $0.007 each, representing a modest 2.5% discount to the five-day volume weighted average price leading up to the plan’s close on 5 June 2026. Each participant will also receive one Attaching Option and one Follow-on Option per share subscribed, offering potential upside if the company’s growth strategy gains traction. The options’ terms and exercise conditions will be subject to shareholder approval at the upcoming Extraordinary General Meeting (EGM) scheduled for 11 June.
Shareholder Approval and Next Steps
The issuance of the SPP shares, along with the second tranche of the institutional placement and the associated options, hinges on shareholder approval at the EGM. If approved, ImpediMed expects to issue the new shares and options on 15 June, with trading commencing the following day. The company has invited shareholders to attend the meeting either in person or online, underscoring the importance of this capital raise in supporting its growth ambitions.
Positioning for Growth in Digital Health Markets
Headquartered in Sydney with operations in the US and Europe, ImpediMed specialises in bioimpedance spectroscopy technology through its SOZO® Digital Health Platform. This FDA-cleared and CE-marked system targets conditions such as lymphoedema and heart failure, markets where the company has been steadily expanding. The capital raise aligns with ImpediMed's efforts to capitalise on its unique positioning in cancer survivorship and related health sectors, building on recent leadership changes and sales momentum reported earlier this month.
Board Chair Highlights Shareholder Confidence
Christine Emmanuel-Donnelly, Chair of the Board, expressed satisfaction with the strong shareholder response, interpreting it as a vote of confidence in the company’s strategy. She emphasised that the support from investors is a critical foundation for ImpediMed’s next growth phase, reflecting optimism about the company’s prospects in a competitive medical technology landscape.
Bottom Line?
The oversubscribed SPP and recent placement bolster ImpediMed’s balance sheet, but the final capital injection depends on shareholder approval next week.
Questions in the middle?
- Will shareholder approval at the EGM proceed smoothly given the scale-back implications?
- How will the attaching and follow-on options impact future dilution and investor returns?
- Can ImpediMed’s SOZO platform sustain momentum amid evolving reimbursement and competitive pressures?
